Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review
- PMID: 18990435
- DOI: 10.1016/j.ygyno.2008.09.036
Variations in institutional infrastructure, physician specialization and experience, and outcome in ovarian cancer: a systematic review
Abstract
Objective: Ovarian cancer outcome varies among different institutions, regions, and countries. This systematic review summarizes the available data evaluating the impact of different physician and hospital characteristics on outcome in ovarian cancer patients.
Methods: A MEDLINE database search for pertinent publications was conducted and reference lists of each relevant article were screened. Experts in the field were contacted. Selected studies assessed the relationship between physician and/or hospital specialty or volume and at least one of the outcomes of interest. The primary outcome was survival. Additional parameters included surgical outcome (debulking), completeness of staging, and quality of chemotherapy. The authors independently reviewed each article and applied the inclusion/exclusion criteria. The quality of each study was assessed by focusing on strategies to control for important prognostic factors.
Results: Forty-four articles met inclusion criteria. Discipline and sub-specialization of the primary treating physician were identified as the most important variable associated with superior outcome. Evidence showing a beneficial impact of institutional factors was weaker, but followed the same trend. Hospital volume was hardly related to any outcome parameter.
Conclusions: The limited evidence available showed considerable heterogeneity and has to be interpreted cautiously. Better utilization of knowledge about institutional factors and well-established board certifications may improve outcome in ovarian cancer. Patients and primary-care physicians should select gynecologic oncologists for primary treatment in countries with established sub-specialty training. Policymakers, insurance companies, and lay organizations should support development of respective programs.
Similar articles
-
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2. Cochrane Database Syst Rev. 2022. PMID: 36161421 Free PMC article.
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
Ultra-radical (extensive) surgery versus standard surgery for the primary cytoreduction of advanced epithelial ovarian cancer.Cochrane Database Syst Rev. 2022 Aug 30;8(8):CD007697. doi: 10.1002/14651858.CD007697.pub3. Cochrane Database Syst Rev. 2022. PMID: 36041232 Free PMC article.
-
Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis.Cochrane Database Syst Rev. 2020 Oct 19;10(10):CD012859. doi: 10.1002/14651858.CD012859.pub2. Cochrane Database Syst Rev. 2020. PMID: 33075160 Free PMC article.
-
Interventions for interpersonal communication about end of life care between health practitioners and affected people.Cochrane Database Syst Rev. 2022 Jul 8;7(7):CD013116. doi: 10.1002/14651858.CD013116.pub2. Cochrane Database Syst Rev. 2022. PMID: 35802350 Free PMC article.
Cited by
-
Apical support at the time of hysterectomy for uterovaginal prolapse.Int Urogynecol J. 2015 Feb;26(2):207-12. doi: 10.1007/s00192-014-2474-y. Epub 2014 Sep 3. Int Urogynecol J. 2015. PMID: 25182150
-
Prediction of Surgical Outcome in Advanced Ovarian Cancer by Imaging and Laparoscopy: A Narrative Review.Cancers (Basel). 2023 Mar 22;15(6):1904. doi: 10.3390/cancers15061904. Cancers (Basel). 2023. PMID: 36980790 Free PMC article. Review.
-
Usefulness of the HE4 biomarker as a second-line test in the assessment of suspicious ovarian tumors.Arch Gynecol Obstet. 2013 Dec;288(6):1377-83. doi: 10.1007/s00404-013-2901-1. Epub 2013 May 31. Arch Gynecol Obstet. 2013. PMID: 23722285 Free PMC article.
-
Impact of institutional accreditation by the Japan Society of Gynecologic Oncology on the treatment and survival of women with cervical cancer.J Gynecol Oncol. 2018 Mar;29(2):e23. doi: 10.3802/jgo.2018.29.e23. Epub 2017 Dec 27. J Gynecol Oncol. 2018. PMID: 29400016 Free PMC article.
-
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.Lancet Oncol. 2022 Aug;23(8):e374-e384. doi: 10.1016/S1470-2045(22)00139-5. Lancet Oncol. 2022. PMID: 35901833 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous